
Operations Office

Telephone 507/266-3853



Date: November 13, 2009

To: NCCTG Primary CRAs, Primary PIs

From: Linda S. Long
Research Protocol Specialist III

Re: N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

The above study will remain open for accrual of 3 additional patients at dose level -1. Per protocol design, temporary closure of the study is not required during the accrual of these patients.

The second cohort of 3 patients in Phase I of the trial has been treated at dose level -1 and preliminary results do not indicate dose limiting toxicities in the first two patients. The next cohort of 3 patients will be enrolled and treated at the same dose level.

If you have any questions concerning this communication, please contact me at 507/266-3853.